Philip Oliver
(Patient)
Philip has over 30 years’ experience in life sciences and new drug development. Much of these evaluating hundreds of potential new oncology and other therapeutics for Eli Lilly as Executive Director of External R&D for Europe. Philip joined Astra Zeneca in 2014 as Director leading European academic and global neuroscience partnerships.
Philip was diagnosed with stage 4 ALK positive NSCLC in 2018. Since then, it has been a rocky journey.
Before his condition worsened markedly, Philip was also for many years Entrepreneur in Residence at Cambridge University, and a Visiting Professor at UCL Medical School. He loved both roles, which involved working closely with scientists from discovery to the clinic and sitting on several MRC grant review committees.
Philip appreciates how fortunate he is to be alive and looks forward to sharing some of his experiences of living with cancer today
Philip was diagnosed with stage 4 ALK positive NSCLC in 2018. Since then, it has been a rocky journey.
Before his condition worsened markedly, Philip was also for many years Entrepreneur in Residence at Cambridge University, and a Visiting Professor at UCL Medical School. He loved both roles, which involved working closely with scientists from discovery to the clinic and sitting on several MRC grant review committees.
Philip appreciates how fortunate he is to be alive and looks forward to sharing some of his experiences of living with cancer today